Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope
Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells found in the tumor microenvironment. TLS can influence primary hepatic carcinoma (PHC) occurrence and have an active role in cancer. TLS can promote or inhibit the growth of PHC depending on their location, and although ava...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.870458/full |
| _version_ | 1811332764774957056 |
|---|---|
| author | Weili Jia Weili Jia Tianchen Zhang Tianchen Zhang Qianyun Yao Jianhui Li Jianhui Li Ye Nie Ye Nie Xinjun Lei Xinjun Lei Zhenzhen Mao Zhenzhen Mao Yanfang Wang Yanfang Wang Wen Shi Wen Shi Wenjie Song |
| author_facet | Weili Jia Weili Jia Tianchen Zhang Tianchen Zhang Qianyun Yao Jianhui Li Jianhui Li Ye Nie Ye Nie Xinjun Lei Xinjun Lei Zhenzhen Mao Zhenzhen Mao Yanfang Wang Yanfang Wang Wen Shi Wen Shi Wenjie Song |
| author_sort | Weili Jia |
| collection | DOAJ |
| description | Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells found in the tumor microenvironment. TLS can influence primary hepatic carcinoma (PHC) occurrence and have an active role in cancer. TLS can promote or inhibit the growth of PHC depending on their location, and although available findings are controversial, they suggest that TLS have a protective role in PHC tissues and a non-protective role in paracancerous tissues. In addition, the cellular composition of TLS can also influence the outcome of PHC. As an immunity marker, TLS can act as a marker of immunotherapy to predict its effect and help to identify patients who will respond well to immunotherapy. Modulation of TLS formation through the use of chemokines/cytokines, immunotherapy, or induction of high endothelial vein to interfere with tumor growth has been studied extensively in PHC and other cancers. In addition, new tools such as genetic interventions, cellular crosstalk, preoperative radiotherapy, and advances in materials science have been shown to influence the prognosis of malignant tumors by modulating TLS production. These can also be used to develop PHC treatment. |
| first_indexed | 2024-04-13T16:41:54Z |
| format | Article |
| id | doaj.art-5b00992db739426aa881536baa02d652 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-13T16:41:54Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-5b00992db739426aa881536baa02d6522022-12-22T02:39:12ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-06-011310.3389/fimmu.2022.870458870458Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow HopeWeili Jia0Weili Jia1Tianchen Zhang2Tianchen Zhang3Qianyun Yao4Jianhui Li5Jianhui Li6Ye Nie7Ye Nie8Xinjun Lei9Xinjun Lei10Zhenzhen Mao11Zhenzhen Mao12Yanfang Wang13Yanfang Wang14Wen Shi15Wen Shi16Wenjie Song17Xi’an Medical University, Xi’an, ChinaDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaXi’an Medical University, Xi’an, ChinaDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaXi’an Medical University, Xi’an, ChinaDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaXi’an Medical University, Xi’an, ChinaDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaXi’an Medical University, Xi’an, ChinaDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaXi’an Medical University, Xi’an, ChinaDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaXi’an Medical University, Xi’an, ChinaDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaXi’an Medical University, Xi’an, ChinaDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaTertiary lymphoid structures (TLSs) are organized aggregates of immune cells found in the tumor microenvironment. TLS can influence primary hepatic carcinoma (PHC) occurrence and have an active role in cancer. TLS can promote or inhibit the growth of PHC depending on their location, and although available findings are controversial, they suggest that TLS have a protective role in PHC tissues and a non-protective role in paracancerous tissues. In addition, the cellular composition of TLS can also influence the outcome of PHC. As an immunity marker, TLS can act as a marker of immunotherapy to predict its effect and help to identify patients who will respond well to immunotherapy. Modulation of TLS formation through the use of chemokines/cytokines, immunotherapy, or induction of high endothelial vein to interfere with tumor growth has been studied extensively in PHC and other cancers. In addition, new tools such as genetic interventions, cellular crosstalk, preoperative radiotherapy, and advances in materials science have been shown to influence the prognosis of malignant tumors by modulating TLS production. These can also be used to develop PHC treatment.https://www.frontiersin.org/articles/10.3389/fimmu.2022.870458/fulltertiary lymphoid structures (TLS)tumor-infiltrating lymphocytes (TIL)primary hepatic carcinoma (PHC)immunotherapycancer prognosisimmune microenvironment (IME) |
| spellingShingle | Weili Jia Weili Jia Tianchen Zhang Tianchen Zhang Qianyun Yao Jianhui Li Jianhui Li Ye Nie Ye Nie Xinjun Lei Xinjun Lei Zhenzhen Mao Zhenzhen Mao Yanfang Wang Yanfang Wang Wen Shi Wen Shi Wenjie Song Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope Frontiers in Immunology tertiary lymphoid structures (TLS) tumor-infiltrating lymphocytes (TIL) primary hepatic carcinoma (PHC) immunotherapy cancer prognosis immune microenvironment (IME) |
| title | Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope |
| title_full | Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope |
| title_fullStr | Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope |
| title_full_unstemmed | Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope |
| title_short | Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope |
| title_sort | tertiary lymphatic structures in primary hepatic carcinoma controversy cannot overshadow hope |
| topic | tertiary lymphoid structures (TLS) tumor-infiltrating lymphocytes (TIL) primary hepatic carcinoma (PHC) immunotherapy cancer prognosis immune microenvironment (IME) |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.870458/full |
| work_keys_str_mv | AT weilijia tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT weilijia tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT tianchenzhang tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT tianchenzhang tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT qianyunyao tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT jianhuili tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT jianhuili tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT yenie tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT yenie tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT xinjunlei tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT xinjunlei tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT zhenzhenmao tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT zhenzhenmao tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT yanfangwang tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT yanfangwang tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT wenshi tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT wenshi tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope AT wenjiesong tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope |